about
Osteoporosis and alzheimer pathology: Role of cellular stress response and hormetic redox signaling in aging and bone remodelingMetabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract.Co-Ultramicronized Palmitoylethanolamide/Luteolin Promotes Neuronal Regeneration after Spinal Cord Injury.Traumatic Brain Injury Leads to Development of Parkinson's Disease Related Pathology in MiceCo-micronized Palmitoylethanolamide/Polydatin Treatment Causes Endometriotic Lesion Regression in a Rodent Model of Surgically Induced Endometriosis.Cellular stress response, sirtuins and UCP proteins in Alzheimer disease: role of vitagenesNew therapeutic strategy for mood disorders.Traumatic brain injury: oxidative stress and neuroprotection.Crude Venom from Nematocysts of the Jellyfish Pelagia noctiluca as a Tool to Study Cell Physiology.A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain modelsN-Palmitoylethanolamine-Oxazoline (PEA-OXA) as a New Therapeutic Strategy to Control Neuroinflammation: Neuroprotective Effects in Experimental Models of Spinal Cord and Brain Injury.Neuroinflammation and Immunity: A New Pharmacological Target in Depression.Inflammasomes, hormesis, and antioxidants in neuroinflammation: Role of NRLP3 in Alzheimer disease.Hormesis, cellular stress response and neuroinflammation in schizophrenia: Early onset versus late onset state.Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism.Reduced adult neurogenesis and altered emotional behaviors in autoimmune-prone B-cell activating factor transgenic mice.The Association of Palmitoylethanolamide with Luteolin Decreases Autophagy in Spinal Cord Injury.The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-κB/Nuclear Transcription Factor Related to NF-E2.Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma.Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia.A novel protective formulation of Palmitoylethanolamide in experimental model of contrast agent induced nephropathy.Erratum to: Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression.Protective effect of polyphenols in an inflammatory process associated with experimental pulmonary fibrosis in mice.PPAR-α Modulates the Anti-Inflammatory Effect of Melatonin in the Secondary Events of Spinal Cord Injury.Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury.Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson's Disease.Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice.Middle Cerebral Artery Occlusion by an Intraluminal Suture Method.2-pentadecyl-2-oxazoline: Identification in coffee, synthesis and activity in a rat model of carrageenan-induced hindpaw inflammation.Adelmidrol, a Palmitoylethanolamide Analogue, as a New Pharmacological Treatment for the Management of Inflammatory Bowel Disease.N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice.2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease.Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect.Ultramicronized palmitoylethanolamide (PEA-um(®)) in the treatment of idiopathic pulmonary fibrosis.Micronized palmitoylethanolamide reduces joint pain and glial cell activationEffect of PEA-OXA on neuropathic pain and functional recovery after sciatic nerve crushThe association of adelmidrol with sodium hyaluronate displays beneficial properties against bladder changes following spinal cord injury in miceRole of Metabotropic Glutamate Receptors in Neurological Disorders
P50
Q27000195-A278CEC4-B1BF-4A27-8F7E-1C8AD35A436FQ34170027-FBAD20D9-670D-4577-B4CA-EF3731C5B5D6Q36663261-20CB6D74-B8AA-414F-8722-F65E97A16C11Q37334985-0627B60D-D704-4E86-A944-232D8C8FF0A8Q37338638-FD0A8D38-560B-413C-8F83-391E10B5A818Q37348049-1F14BEEB-8D06-4FDB-BA0E-507C321D7D62Q37921357-1BF599E4-8E8D-4662-AB94-329D5FCED8C7Q38095084-ADF2F6C2-A506-48B6-B4DB-BEA965B7FB88Q38263593-CCEFA52C-3512-4809-B09F-5F811271392DQ38646217-814FEF64-AB97-4633-AABE-7AADB6279728Q38720918-50FBC0C7-5AC3-49E7-B548-4BB4005E0348Q38782164-FBD77C63-F50E-4147-9247-B0C94DE101F7Q39012955-2040436D-2319-46EF-9D56-12305A165AF5Q39023447-75F5743B-8ABC-4233-8803-075EAE5E72ECQ39324090-190381CC-9AF2-41E5-920F-83BCB6BECD80Q39897386-93CFC3C5-9D32-4A0A-9BF6-A311FDACAE32Q40768333-52D6DD09-614C-4ECA-981C-010CDFC73B19Q41467663-D907402F-8C80-4E26-A426-B30514A65DCEQ41912809-B6740AC6-A12E-4B77-A107-F964984DFD7CQ42176106-CC57676F-A37C-4B04-A099-271285395315Q42220056-6F9F733E-19A0-4FA3-A08E-7AFA87BB2538Q42700347-569B04E6-79D8-4203-A645-6BA7EDFA303DQ42747161-2430A29D-A413-4C26-A106-9A679F234088Q44217081-A82C2823-78A1-4A4A-B940-E9682E32C3C9Q46675316-2DA0F9AC-2EBC-41CA-8AA2-7A69E2E5FCBAQ48054392-3B47231E-7AF6-4A99-A06F-E9AA7BA9A867Q48108674-E9CC9AD7-3E30-463B-B599-7FD3E29ABE05Q48238673-23D40747-1BD7-4E98-8EE3-D1CAFFB1496DQ48412547-BF55FE18-1A40-42F0-8CDC-0E81876A936AQ49985594-6E96F90A-370E-4AF2-9084-4725D490AAAEQ50042498-4A6266C2-859D-4A11-8EF2-6E50D07ABB50Q51510329-5E45C22E-7C0E-40BB-9846-54F11200C522Q51761851-8CCD1584-E41B-4AAA-961E-52C6BF0B48E3Q52587860-D930D1ED-E12F-4736-8604-21131770BD3BQ52608759-9E9CDD63-4735-4BC7-B17B-FF50EF8617CBQ53063329-46E9443A-9F35-44F2-A937-35FF1862D886Q56342104-FD790C9F-9352-4F9D-9B6F-0DC11BDF1598Q58741796-8087B90B-62E5-4E60-8E78-7AF30273EFDFQ61447096-8F2C5619-DE28-4C59-A575-CA0215F42E83Q64244146-007DA70E-A4D6-4215-96FB-D7FBAC4C26B2
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Rosalia Crupi
@en
Rosalia Crupi
@nl
type
label
Rosalia Crupi
@en
Rosalia Crupi
@nl
prefLabel
Rosalia Crupi
@en
Rosalia Crupi
@nl
P31
P496
0000-0002-7629-3132